Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Heron Therapeutics stock | 18.36

Own Heron Therapeutics stock in just a few minutes.


Fact checked

Heron Therapeutics, Inc is a biotechnology business based in the US. Heron Therapeutics shares (HRTX) are listed on the NASDAQ and all prices are listed in US Dollars. Heron Therapeutics employs 231 staff and has a trailing 12-month revenue of around USD$125.8 million.

How to buy shares in Heron Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Heron Therapeutics. Find the stock by name or ticker symbol: HRTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Heron Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$18.36, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Heron Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Heron Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

How has coronavirus impacted Heron Therapeutics's share price?

Since the stock market crash in March caused by coronavirus, Heron Therapeutics's share price has had significant negative movement.

Its last market close was USD$18.36, which is 14.41% down on its pre-crash value of USD$21.45 and 91.25% up on the lowest point reached during the March crash when the shares fell as low as USD$9.6.

If you had bought USD$1,000 worth of Heron Therapeutics shares at the start of February 2020, those shares would have been worth USD$522.35 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$881.46.

Heron Therapeutics share price

Use our graph to track the performance of HRTX stocks over time.

Heron Therapeutics shares at a glance

Information last updated 2020-10-20.
Latest market close USD$18.36
52-week range USD$9.6 - USD$26.81
50-day moving average USD$15.0462
200-day moving average USD$15.9903
Wall St. target price USD$31.2
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-2.562

Buy Heron Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Stocks, Mutual funds, ETFs, Forex
$20 per year
Get a personal advisor when you open an account with at least $50,000.
Stocks, Options, ETFs, Cryptocurrency
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, Index funds, ETFs, Futures, Cash
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
TD Ameritrade
or $25 broker-assisted
$0 + $0.65/contract,
or $25 broker-assisted
TD Ameritrade features $0 commission for online stock, but watch out for high short-term ETF and broker-assisted trading fees.

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Heron Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Heron Therapeutics price performance over time

Historical closes compared with the close of $18.36 from 2020-11-16

1 week (2020-11-20) -0.33%
1 month (2020-10-30) 12.57%
3 months (2020-08-28) 29.30%
6 months (2020-05-29) 0.77%
1 year (2019-11-29) -28.17%
2 years (2018-11-29) -34.55%
3 years (2017-11-29) 8.32%
5 years (2015-11-27) -38.35%

Heron Therapeutics financials

Revenue TTM USD$125.8 million
Gross profit TTM USD$-83,033,000
Return on assets TTM -30.01%
Return on equity TTM -63.01%
Profit margin -157.65%
Book value $3.568
Market capitalisation USD$1.4 billion

TTM: trailing 12 months

Shorting Heron Therapeutics shares

There are currently 17.0 million Heron Therapeutics shares held short by investors – that's known as Heron Therapeutics's "short interest". This figure is 10.5% up from 15.4 million last month.

There are a few different ways that this level of interest in shorting Heron Therapeutics shares can be evaluated.

Heron Therapeutics's "short interest ratio" (SIR)

Heron Therapeutics's "short interest ratio" (SIR) is the quantity of Heron Therapeutics shares currently shorted divided by the average quantity of Heron Therapeutics shares traded daily (recently around 891951.07273679). Heron Therapeutics's SIR currently stands at 19.11. In other words for every 100,000 Heron Therapeutics shares traded daily on the market, roughly 19110 shares are currently held short.

However Heron Therapeutics's short interest can also be evaluated against the total number of Heron Therapeutics shares, or, against the total number of tradable Heron Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Heron Therapeutics's short interest could be expressed as 0.19% of the outstanding shares (for every 100,000 Heron Therapeutics shares in existence, roughly 190 shares are currently held short) or 0.2283% of the tradable shares (for every 100,000 tradable Heron Therapeutics shares, roughly 228 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Heron Therapeutics.

Find out more about how you can short Heron Therapeutics stock.

Heron Therapeutics share dividends

We're not expecting Heron Therapeutics to pay a dividend over the next 12 months.

Have Heron Therapeutics's shares ever split?

Heron Therapeutics's shares were split on a 1:20 basis on 13 January 2014. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Heron Therapeutics shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Heron Therapeutics shares which in turn could have impacted Heron Therapeutics's share price.

Heron Therapeutics share price volatility

Over the last 12 months, Heron Therapeutics's shares have ranged in value from as little as $9.6 up to $26.81. A popular way to gauge a stock's volatility is its "beta".

HRTX.US volatility(beta: 1.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Heron Therapeutics's is 1.6227. This would suggest that Heron Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Heron Therapeutics overview

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam that is in Phase III clinical trial for pain management; and HTX-034, a product candidate for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site